Evidence map›Paper›PMID 34775966›Full record

ArticleBMC pulmonary medicine2021

Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies.

Abhinav K Misra, Nathan L Wong, Terrance T Healey, Edward V Lally, Barry S Shea

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Abhinav K MisraDivision of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital and Alpert Medical School of Brown University, 593 Eddy Street, POB 224, Providence, RI, 02903, USA.
Nathan L WongDepartment of Medicine, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA.
Terrance T HealeyDepartment of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA.
Edward V LallyDivision of Rheumatology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA.
Barry S SheaDivision of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital and Alpert Medical School of Brown University, 593 Eddy Street, POB 224, Providence, RI, 02903, USA. bsshea@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-3205-026X
Brown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs.

methodsWe identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM/DM-associated ILD and those with ILD but no muscle or skin disease.

resultsA total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (p < 0.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival.

conclusionsIn this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM/DM.

Indexed as

Adrenal Cortex HormonesAdultAgedAged, 80 and overAutoantibodiesDisease ProgressionFemaleHumansLung Diseases, InterstitialMaleMiddle AgedMyositisRhode IslandAdrenal Cortex HormonesAutoantibodiesDermatomyositisInterstitial lung diseaseMyositis-specific antibodiesPolymyositis

Identifiers

PMID34775966
PMCPMC8591876
OpenAlexW3213687270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.